Current Opinion in Immunology· 2026Q1· Review
The complex pathophysiology of chronic nonbacterial osteitis (CNO) and how it informs treatment
- 0citations
- Q1SCImago
- 2026year
Short summary
Rare variants in the P2RX7 gene, encoding the P2X7 receptor, are linked to pathological inflammasome activation in up to 40% of chronic nonbacterial osteitis (CNO) patients, explaining clinical response to anti-inflammatory treatments.
AI-generated from the title and abstract; the full text is not read.
Key points
- CNO pathophysiology involves inflammasome activation and cytokine dysregulation.
- Altered mitogen-activated protein kinases and reduced IL-10 impair inflammasome inhibition.
- Rare P2RX7 gene variants are found in up to 40% of CNO patients, causing pathological inflammasome activation.
- Current treatments targeting inflammation or osteoclasts are effective due to these mechanisms.
- Secondary adaptive immune activation may explain expanded clinical phenotypes.
AI-generated from the title and abstract; the full text is not read.
Abstract
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease characterized by pathological inflammasome activation and a pronounced dysregulation of cytokine expression. Recent advances have linked pathological activation of mitogen-activated protein kinases with altered expression of immune-regulatory interleukin-10, resulting in impaired inhibition of inflammasomes. Moreover, rare variants in the P2RX7 gene, encoding for the ATP-dependent P2X7 surface receptor, have been linked with pathological activation of inflammasomes in up to 40% of people with CNO. These observations explain clinical response to currently used off-label treatments targeting inflammation and/or osteoclasts. An expanded clinical phenotype with skin, joint, and/or gut involvement may be the result of a secondary activation of adaptive immune mechanisms. In patients with synovitis, acne, pustulosis hyperostotic and osteitis, lymphocyte activation may be responsible for the development of additional organ involvement. This manuscript summarizes recent advances in the understanding of CNO, discussing the possibility of future disease stage and phenotype-specific treatment.
The authors' abstract, as published at the source. Current Opinion in Immunology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Rheumatology
RheumatologyMedicine